Prognostic value of early [ 18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 1, 2011, Pages 176-184

  Piroth, Marc D ^a,c   Pinkawa, Michael ^a,c   Holy, Richard ^a,c   Klotz, Jens ^a,c   Nussen, Sandra ^a,c   Stoffels, Gabriele ^b,c   Coenen, Heinz H ^b,c   Kaiser, Hans J ^a   Langen, Karl J ^b,c   Eble, Michael J ^a,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c Juelich Aachen Research Alliance   (Germany)

Author keywords

18F fluoroethyl) L tyrosine positron emission tomography; Early response; Glioblastoma; Radiochemotherapy; Radiotherapy

Indexed keywords

[ 18F]FLUOROETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; EARLY DETECTION; EARLY RESPONSE; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS; OVERALL SURVIVAL; PROSPECTIVE STUDY; RADIOCHEMOTHERAPY; STATISTICALLY SIGNIFICANT DIFFERENCE; TREATMENT MONITORING; TREATMENT RESPONSE; TUMOR PROGRESSIONS;

AMINO ACIDS; BREEDER REACTORS; ELECTRONS; MAGNETIC RESONANCE IMAGING; MESFET DEVICES; POSITRONS; RADIOTHERAPY; RESONANCE; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

FLUOROETHYLTYROSINE F18; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG UPTAKE; EARLY DIAGNOSIS; FEMALE; GLIOBLASTOMA; HUMAN; MALE; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TYROSINE;

EID: 78650257188     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.055     Document Type: Article

References (40)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
2. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
3. R. Stupp, M.E. Hegi, and M.R. Gilbert Chemoradiotherapy in malignant glioma: Standard of care and future directions J Clin Oncol 25 2007 4127 4136 (Pubitemid 47492957)
4. Y. Cao, C.I. Tsien, and Z. Shen Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy J Clin Oncol 23 2005 4127 4136 (Pubitemid 46211318)
5. A.J. Kumar, N.E. Leeds, and G.N. Fuller Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy induced necrosis of the brain after treatment Radiology 217 2000 377 384
6. R.A. Lustig, W. Seiferheld, and B. Berkey Imaging response in malignant glioma, RTOG 90-06 Am J Clin Oncol 30 2007 32 37 (Pubitemid 46213822)
7. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
8. D. Brandsma, L. Stalpers, and W. Taal Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 2008 453 461 (Pubitemid 351597795)
9. M.C. Chamberlain, M.J. Glantz, and L. Chalmers Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 2007 81 83
10. I. Yang, and M.K. Aghi New advances that enable identification of glioblastoma recurrence Nat Rev Clin Oncol 6 2009 648 657
11. T. Singhal, T.K. Narayanan, and V. Jain 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas Mol Imaging Biol 10 2008 1 18
12. K. Hamacher, and H.H. Coenen Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine Appl Radiat Isot 57 2002 853 856 (Pubitemid 35284220)
13. K.J. Langen, K. Hamacher, and M. Weckesser O-(2-[18F]fluoroethyl)-L- tyrosine: Uptake mechanisms and clinical applications Nucl Med Biol 33 2006 287 294
14. H.J. Wester, M. Herz, and W. Weber Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging J Nucl Med 40 1999 205 212 (Pubitemid 29044193)
15. F.W. Floeth, D. Pauleit, and H.J. Wittsack Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L- tyrosine and magnetic resonance spectroscopy J Neurosurg 102 2005 318 327 (Pubitemid 43194083)
16. D. Pauleit, F. Floeth, and K. Hamacher O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas Brain 128 2005 678 687 (Pubitemid 40380202)
17. G. Popperl, C. Gotz, and W. Rachinger Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma Eur J Nucl Med Mol Imaging 31 2004 1464 1470 (Pubitemid 39592765)
18. W. Rachinger, C. Goetz, and G. Popperl Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas Neurosurgery 57 2005 505 511 (Pubitemid 41254459)
19. F.W. Floeth, D. Pauleit, and M. Sabel Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma J Nucl Med 48 2007 519 527 (Pubitemid 47571405)
20. G. Popperl, R. Goldbrunner, and F.J. Gildehaus O-(2-[18F]fluoroethyl)-L- tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma Eur J Nucl Med Mol Imaging 32 2005 1018 1025 (Pubitemid 41339276)
21. G. Popperl, C. Gotz, and W. Rachinger Serial O-(2-[(18)F]fluoroethyl)-L- tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma Eur J Nucl Med Mol Imaging 33 2006 792 800 (Pubitemid 43979687)
22. M. Wyss, S. Hofer, and M. Bruehlmeier Early metabolic responses in temozolomide treated low-grade glioma patients J Neurooncol 95 2009 87 93
23. W.J. Curran Jr., C.B. Scott, and J. Horton Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 1993 704 710 (Pubitemid 23133591)
24. P. Roesch, T. Netsch, and T. McNutt Syntegra: Automated image registration algorithms Philips White Paper 2003
25. M.D. Piroth, M. Pinkawa, and R. Holy Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme: A dosimetric comparison Radiat Oncol 4 2009 57
26. M. Weckesser, K.J. Langen, and C.H. Rickert O-(2-[18F]fluorethyl)-L- tyrosine PET in the clinical evaluation of primary brain tumours Eur J Nucl Med Mol Imaging 32 2005 422 429 (Pubitemid 40591174)
27. Prescribing, recording and reporting photon beam therapy Journal of the International Commission on Radiation Units and Measurements 1993
28. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU 50 Report) Journal of the International Commission on Radiation Units and Measurements 1999
29. J.L. Chan, S.W. Lee, and B.A. Fraass Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy J Clin Oncol 20 2002 1635 1642 (Pubitemid 34260545)
30. D.R. Macdonald, T.L. Cascino, and S.C. Schold Jr. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280 (Pubitemid 20195640)
31. K.J. Langen, N. Roosen, and H.H. Coenen Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L amino acids J Nucl Med 32 1991 1225 1229
32. R.T. Ullrich, L. Kracht, and A. Brunn Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma J Nucl Med 50 2009 1962 1968
33. N. Galldiks, L.W. Kracht, and L. Burghaus Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas Eur J Nucl Med Mol Imaging 33 2006 516 524
34. A.H. Jacobs, A. Thomas, and L.W. Kracht 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors J Nucl Med 46 2005 1948 1958 (Pubitemid 46657440)
35. C. Balmaceda, D. Critchell, and X. Mao Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy J Neurooncol 76 2006 185 191 (Pubitemid 43125747)
36. A. Stadlbauer, O. Prante, and C. Nimsky Metabolic imaging of cerebral gliomas: Spatial correlation of changes in O-(2 18F-fluoroethyl)-L tyrosine PET and proton magnetic resonance spectroscopic imaging J Nucl Med 49 2008 721 729 (Pubitemid 351717536)
37. M.J. van den Bent, and J.M. Kros Predictive and prognostic markers in neuro-oncology J Neuropathol Exp Neurol 66 2007 1074 1081 (Pubitemid 350294657)
38. S. Yip, A.J. Iafrate, and D.N. Louis Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers J Neuropathol Exp Neurol 67 2008 1 15
39. M.E. Hegi, L. Liu, and J.G. Herman Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26 2008 4189 4199
40. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003 (Pubitemid 40349502)